Watching the Watchdog: How Does ICER Determine ‘Fair’ Prices for Drugs?

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Aducanumab & the Alzheimer’s Moonshot: What Would It Be Worth to Keep Your Mind?
Capturing Family History, While We Have Time
COVID-19’s Unexpected Silver Lining: A Chance at Redemption for US Healthcare
COVID-19 Response – the Roadmap Not Followed